| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clozapine | 45 | 2024 | 509 | 7.960 |
Why?
|
| Antipsychotic Agents | 81 | 2024 | 3078 | 7.400 |
Why?
|
| Schizophrenia | 107 | 2024 | 6976 | 5.770 |
Why?
|
| Schizophrenic Psychology | 37 | 2019 | 1647 | 2.270 |
Why?
|
| Catatonia | 5 | 2023 | 181 | 1.840 |
Why?
|
| Psychotic Disorders | 31 | 2024 | 3275 | 1.810 |
Why?
|
| Psychiatry | 14 | 2018 | 1715 | 1.580 |
Why?
|
| Neutropenia | 4 | 2021 | 895 | 1.330 |
Why?
|
| Mental Disorders | 15 | 2023 | 6869 | 1.300 |
Why?
|
| Referral and Consultation | 9 | 2024 | 3618 | 0.900 |
Why?
|
| Delayed-Action Preparations | 8 | 2023 | 966 | 0.900 |
Why?
|
| Stuttering | 1 | 2023 | 24 | 0.860 |
Why?
|
| Plague | 1 | 2023 | 20 | 0.850 |
Why?
|
| Electroconvulsive Therapy | 3 | 2024 | 505 | 0.840 |
Why?
|
| Physician's Role | 6 | 2016 | 925 | 0.820 |
Why?
|
| Risperidone | 9 | 2023 | 383 | 0.810 |
Why?
|
| Physician-Patient Relations | 9 | 2016 | 3266 | 0.770 |
Why?
|
| Psychophysiologic Disorders | 2 | 2016 | 222 | 0.770 |
Why?
|
| Somatoform Disorders | 2 | 2016 | 425 | 0.710 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 109 | 0.710 |
Why?
|
| Antiviral Agents | 4 | 2016 | 3070 | 0.700 |
Why?
|
| Ileus | 1 | 2020 | 65 | 0.680 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3110 | 0.650 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 3232 | 0.650 |
Why?
|
| Schizophrenia, Paranoid | 4 | 2010 | 102 | 0.640 |
Why?
|
| Treatment Refusal | 3 | 2016 | 433 | 0.620 |
Why?
|
| Phencyclidine | 1 | 2018 | 59 | 0.620 |
Why?
|
| Sialorrhea | 4 | 2005 | 25 | 0.590 |
Why?
|
| Delirium | 4 | 2020 | 1698 | 0.570 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2017 | 33 | 0.570 |
Why?
|
| Psychosomatic Medicine | 2 | 2015 | 72 | 0.560 |
Why?
|
| Hepatitis C | 3 | 2016 | 1595 | 0.560 |
Why?
|
| Tetrabenazine | 1 | 2017 | 21 | 0.560 |
Why?
|
| Haloperidol | 4 | 2014 | 394 | 0.550 |
Why?
|
| Decision Making | 5 | 2014 | 3951 | 0.550 |
Why?
|
| Community Psychiatry | 2 | 2016 | 19 | 0.550 |
Why?
|
| Patient Compliance | 5 | 2016 | 2694 | 0.550 |
Why?
|
| Ribavirin | 2 | 2010 | 396 | 0.540 |
Why?
|
| Medication Adherence | 6 | 2022 | 2190 | 0.540 |
Why?
|
| Humans | 179 | 2024 | 766812 | 0.530 |
Why?
|
| Triazines | 1 | 2018 | 311 | 0.530 |
Why?
|
| Behavioral Symptoms | 2 | 2016 | 188 | 0.520 |
Why?
|
| Mental Competency | 2 | 2014 | 179 | 0.520 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 186 | 0.520 |
Why?
|
| Internship and Residency | 8 | 2018 | 5943 | 0.520 |
Why?
|
| Valine | 2 | 2017 | 410 | 0.520 |
Why?
|
| Uridine Monophosphate | 1 | 2016 | 67 | 0.510 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 780 | 0.490 |
Why?
|
| Psychophysiology | 1 | 2015 | 136 | 0.490 |
Why?
|
| Fluorenes | 1 | 2016 | 160 | 0.480 |
Why?
|
| Communicable Diseases | 2 | 2023 | 872 | 0.480 |
Why?
|
| Tobacco Use Disorder | 4 | 2019 | 708 | 0.480 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 128 | 0.470 |
Why?
|
| Interferons | 2 | 2010 | 716 | 0.470 |
Why?
|
| Legal Guardians | 2 | 2016 | 59 | 0.470 |
Why?
|
| Quinolones | 4 | 2012 | 389 | 0.470 |
Why?
|
| Self-Help Groups | 1 | 2016 | 194 | 0.470 |
Why?
|
| Dissent and Disputes | 2 | 2015 | 150 | 0.470 |
Why?
|
| Secondary Prevention | 1 | 2021 | 1469 | 0.460 |
Why?
|
| Palmitates | 1 | 2014 | 68 | 0.460 |
Why?
|
| Benzimidazoles | 2 | 2017 | 862 | 0.460 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 857 | 0.450 |
Why?
|
| Smoking Cessation | 9 | 2019 | 2085 | 0.440 |
Why?
|
| HIV Infections | 7 | 2016 | 17532 | 0.440 |
Why?
|
| Professional Role | 1 | 2016 | 314 | 0.440 |
Why?
|
| Benzodiazepines | 12 | 2018 | 1137 | 0.410 |
Why?
|
| Isoxazoles | 1 | 2014 | 233 | 0.410 |
Why?
|
| Vulnerable Populations | 3 | 2014 | 718 | 0.410 |
Why?
|
| Publications | 1 | 2015 | 195 | 0.410 |
Why?
|
| Biological Psychiatry | 2 | 2010 | 27 | 0.400 |
Why?
|
| Drug Monitoring | 3 | 2020 | 962 | 0.400 |
Why?
|
| Myocarditis | 2 | 2021 | 802 | 0.390 |
Why?
|
| Adult | 93 | 2024 | 223305 | 0.380 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2013 | 1988 | 0.380 |
Why?
|
| Social Responsibility | 2 | 2012 | 382 | 0.380 |
Why?
|
| Internet | 2 | 2016 | 3113 | 0.370 |
Why?
|
| Morgellons Disease | 1 | 2010 | 4 | 0.370 |
Why?
|
| Citalopram | 4 | 2023 | 402 | 0.370 |
Why?
|
| AIDS Dementia Complex | 1 | 2012 | 154 | 0.370 |
Why?
|
| Piperazines | 6 | 2012 | 2547 | 0.360 |
Why?
|
| Patient Discharge | 2 | 2014 | 3466 | 0.360 |
Why?
|
| Neurosciences | 1 | 2015 | 384 | 0.360 |
Why?
|
| Gender Identity | 1 | 2016 | 767 | 0.350 |
Why?
|
| Inservice Training | 1 | 2012 | 374 | 0.340 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2019 | 490 | 0.340 |
Why?
|
| Central Nervous System Stimulants | 3 | 2009 | 1168 | 0.340 |
Why?
|
| Models, Educational | 1 | 2012 | 375 | 0.340 |
Why?
|
| Lithium Carbonate | 1 | 2010 | 179 | 0.330 |
Why?
|
| Prolactinoma | 1 | 2010 | 114 | 0.330 |
Why?
|
| Male | 100 | 2024 | 364154 | 0.330 |
Why?
|
| Polypharmacy | 1 | 2012 | 307 | 0.320 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2010 | 98 | 0.320 |
Why?
|
| Pandemics | 5 | 2023 | 8734 | 0.320 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5367 | 0.320 |
Why?
|
| Duodenum | 1 | 2012 | 495 | 0.310 |
Why?
|
| Psychiatric Status Rating Scales | 20 | 2019 | 6020 | 0.300 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 663 | 0.300 |
Why?
|
| Fatigue | 3 | 2010 | 1555 | 0.300 |
Why?
|
| Health Literacy | 1 | 2013 | 466 | 0.300 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1033 | 0.290 |
Why?
|
| Cooperative Behavior | 5 | 2016 | 1512 | 0.290 |
Why?
|
| Drug Therapy, Combination | 17 | 2019 | 6306 | 0.290 |
Why?
|
| Middle Aged | 70 | 2024 | 223267 | 0.290 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 935 | 0.280 |
Why?
|
| Epilepsy | 1 | 2022 | 3317 | 0.280 |
Why?
|
| Models, Psychological | 3 | 2010 | 823 | 0.280 |
Why?
|
| Female | 94 | 2024 | 396532 | 0.270 |
Why?
|
| Diagnosis, Differential | 15 | 2019 | 12985 | 0.270 |
Why?
|
| Double-Blind Method | 27 | 2019 | 12430 | 0.270 |
Why?
|
| Patient Preference | 1 | 2014 | 946 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 2 | 2012 | 939 | 0.270 |
Why?
|
| Metabolic Diseases | 5 | 2013 | 686 | 0.260 |
Why?
|
| Cognition Disorders | 10 | 2014 | 3967 | 0.260 |
Why?
|
| Malingering | 1 | 2006 | 76 | 0.260 |
Why?
|
| Benzhydryl Compounds | 2 | 2011 | 944 | 0.260 |
Why?
|
| Abbreviations as Topic | 1 | 2005 | 8 | 0.260 |
Why?
|
| Social Behavior | 2 | 2012 | 1147 | 0.250 |
Why?
|
| Vaccination | 3 | 2023 | 3435 | 0.250 |
Why?
|
| Indans | 1 | 2005 | 92 | 0.240 |
Why?
|
| HIV Seropositivity | 1 | 2010 | 962 | 0.240 |
Why?
|
| Bradycardia | 1 | 2007 | 304 | 0.240 |
Why?
|
| Self Psychology | 1 | 2004 | 8 | 0.240 |
Why?
|
| Prochlorperazine | 1 | 2004 | 16 | 0.230 |
Why?
|
| Aphonia | 1 | 2004 | 4 | 0.230 |
Why?
|
| Emetics | 1 | 2004 | 9 | 0.230 |
Why?
|
| Psychopharmacology | 1 | 2006 | 146 | 0.230 |
Why?
|
| Ipratropium | 1 | 2004 | 19 | 0.230 |
Why?
|
| Neuropsychological Tests | 14 | 2019 | 7119 | 0.230 |
Why?
|
| Administration, Sublingual | 1 | 2004 | 60 | 0.230 |
Why?
|
| Community Mental Health Services | 2 | 2021 | 386 | 0.220 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 746 | 0.220 |
Why?
|
| Curriculum | 2 | 2018 | 3783 | 0.220 |
Why?
|
| Salivary Glands | 1 | 2005 | 231 | 0.220 |
Why?
|
| Depression | 6 | 2019 | 8225 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 550 | 0.220 |
Why?
|
| Bupropion | 4 | 2007 | 303 | 0.220 |
Why?
|
| Coma | 1 | 2007 | 485 | 0.210 |
Why?
|
| Pirenzepine | 1 | 2003 | 116 | 0.210 |
Why?
|
| Lorazepam | 2 | 2018 | 155 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4570 | 0.200 |
Why?
|
| Bipolar Disorder | 5 | 2020 | 5130 | 0.200 |
Why?
|
| Quality of Life | 4 | 2019 | 13476 | 0.200 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4880 | 0.200 |
Why?
|
| Adrenergic Antagonists | 1 | 2002 | 26 | 0.200 |
Why?
|
| Evidence-Based Medicine | 4 | 2013 | 3692 | 0.200 |
Why?
|
| Priapism | 1 | 2002 | 28 | 0.200 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2008 | 276 | 0.200 |
Why?
|
| Treatment Outcome | 25 | 2021 | 65286 | 0.200 |
Why?
|
| Antipyretics | 1 | 2021 | 22 | 0.190 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 1324 | 0.190 |
Why?
|
| Communication | 1 | 2016 | 3905 | 0.190 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 556 | 0.190 |
Why?
|
| Attitude to Health | 5 | 2009 | 2021 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2012 | 10745 | 0.190 |
Why?
|
| Frontal Lobe | 2 | 2006 | 1408 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 1445 | 0.190 |
Why?
|
| Autonomic Dysreflexia | 1 | 2001 | 9 | 0.180 |
Why?
|
| Pilot Projects | 8 | 2022 | 8728 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 1911 | 0.180 |
Why?
|
| Dystonia | 1 | 2004 | 378 | 0.180 |
Why?
|
| Piperidines | 2 | 2007 | 1663 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 2418 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 858 | 0.170 |
Why?
|
| Personal Autonomy | 2 | 2012 | 316 | 0.170 |
Why?
|
| Education, Medical | 1 | 2011 | 1744 | 0.170 |
Why?
|
| Outpatients | 3 | 2023 | 1596 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2903 | 0.160 |
Why?
|
| Forensic Psychiatry | 2 | 2014 | 198 | 0.160 |
Why?
|
| Hippocampus | 5 | 2023 | 3776 | 0.160 |
Why?
|
| Anemia, Pernicious | 1 | 2019 | 16 | 0.160 |
Why?
|
| Nitroprusside | 1 | 2019 | 271 | 0.160 |
Why?
|
| Insulin | 7 | 2019 | 6608 | 0.160 |
Why?
|
| Hypoglycemic Agents | 4 | 2013 | 3108 | 0.160 |
Why?
|
| Colonic Diseases | 1 | 2000 | 204 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2012 | 2011 | 0.160 |
Why?
|
| Nicotine | 6 | 2008 | 680 | 0.160 |
Why?
|
| Placebos | 6 | 2009 | 1659 | 0.160 |
Why?
|
| Perphenazine | 1 | 2018 | 33 | 0.160 |
Why?
|
| Intestinal Perforation | 1 | 2000 | 254 | 0.160 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 4628 | 0.150 |
Why?
|
| Affect | 3 | 2007 | 1494 | 0.150 |
Why?
|
| Peritonitis | 1 | 2000 | 368 | 0.150 |
Why?
|
| Hospitals, General | 1 | 2003 | 804 | 0.150 |
Why?
|
| Recurrence | 4 | 2021 | 8507 | 0.150 |
Why?
|
| Lipid Metabolism | 5 | 2014 | 1895 | 0.150 |
Why?
|
| Paresthesia | 1 | 2019 | 159 | 0.150 |
Why?
|
| Caregivers | 1 | 2010 | 2303 | 0.150 |
Why?
|
| Dopamine | 2 | 2008 | 1581 | 0.150 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 228 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2021 | 540 | 0.140 |
Why?
|
| Acetaminophen | 1 | 2021 | 549 | 0.140 |
Why?
|
| Thiazolidinediones | 2 | 2012 | 460 | 0.140 |
Why?
|
| Neutrophils | 1 | 2010 | 3782 | 0.140 |
Why?
|
| Gene Expression | 1 | 2010 | 7585 | 0.140 |
Why?
|
| Vitamin B 12 | 2 | 2019 | 531 | 0.140 |
Why?
|
| Ambulatory Care | 5 | 2008 | 2779 | 0.140 |
Why?
|
| Nicotinic Agonists | 3 | 2008 | 265 | 0.140 |
Why?
|
| Prolactin | 2 | 2010 | 628 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2010 | 3799 | 0.140 |
Why?
|
| Primary Health Care | 2 | 2019 | 4735 | 0.130 |
Why?
|
| Delusions | 1 | 2019 | 300 | 0.130 |
Why?
|
| Posture | 1 | 2001 | 955 | 0.130 |
Why?
|
| Stereotyping | 2 | 2011 | 241 | 0.130 |
Why?
|
| Teaching | 1 | 2004 | 1171 | 0.130 |
Why?
|
| Carcinoma, Ductal | 1 | 2016 | 96 | 0.130 |
Why?
|
| Liver | 1 | 2012 | 7571 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2010 | 1606 | 0.130 |
Why?
|
| Benzoates | 1 | 2017 | 213 | 0.130 |
Why?
|
| Cyclobutanes | 2 | 2007 | 57 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2018 | 958 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2586 | 0.130 |
Why?
|
| Appetite Depressants | 2 | 2007 | 108 | 0.120 |
Why?
|
| Awareness | 3 | 2009 | 653 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 560 | 0.120 |
Why?
|
| Weight Gain | 4 | 2013 | 2356 | 0.120 |
Why?
|
| Blood Glucose | 9 | 2011 | 6422 | 0.120 |
Why?
|
| Community Health Services | 1 | 2020 | 659 | 0.120 |
Why?
|
| Amantadine | 1 | 1995 | 58 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2023 | 2764 | 0.120 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2008 | 242 | 0.120 |
Why?
|
| Head Injuries, Closed | 1 | 1996 | 133 | 0.120 |
Why?
|
| Models, Biological | 2 | 2010 | 9464 | 0.120 |
Why?
|
| Cytokines | 1 | 2010 | 7438 | 0.120 |
Why?
|
| Immunoassay | 1 | 2018 | 744 | 0.120 |
Why?
|
| Body Weight | 8 | 2019 | 4626 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 428 | 0.120 |
Why?
|
| Self Care | 1 | 2020 | 800 | 0.120 |
Why?
|
| Mass Screening | 2 | 2007 | 5454 | 0.120 |
Why?
|
| Chronic Disease | 7 | 2013 | 9358 | 0.120 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1995 | 165 | 0.120 |
Why?
|
| Administration, Intranasal | 4 | 2013 | 482 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 1404 | 0.110 |
Why?
|
| Cellulitis | 1 | 2016 | 206 | 0.110 |
Why?
|
| Suicide | 1 | 2005 | 1606 | 0.110 |
Why?
|
| Aged | 20 | 2022 | 171344 | 0.110 |
Why?
|
| Boston | 2 | 2021 | 9346 | 0.110 |
Why?
|
| Health Personnel | 2 | 2023 | 3384 | 0.110 |
Why?
|
| Homocysteine | 3 | 2007 | 638 | 0.110 |
Why?
|
| Clinical Competence | 3 | 2018 | 4858 | 0.110 |
Why?
|
| Halfway Houses | 1 | 2013 | 11 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 7430 | 0.110 |
Why?
|
| Group Processes | 1 | 2015 | 225 | 0.110 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2005 | 286 | 0.110 |
Why?
|
| Hallucinations | 1 | 1996 | 373 | 0.100 |
Why?
|
| Cross-Sectional Studies | 12 | 2019 | 26309 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2016 | 3724 | 0.100 |
Why?
|
| Cognition | 4 | 2013 | 7057 | 0.100 |
Why?
|
| Massachusetts | 4 | 2020 | 8890 | 0.100 |
Why?
|
| Pravastatin | 1 | 2014 | 391 | 0.100 |
Why?
|
| Comorbidity | 8 | 2015 | 10580 | 0.100 |
Why?
|
| Young Adult | 9 | 2022 | 59939 | 0.100 |
Why?
|
| Anthropometry | 4 | 2011 | 1336 | 0.100 |
Why?
|
| Insulin Resistance | 7 | 2010 | 3989 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 2662 | 0.100 |
Why?
|
| Waist Circumference | 3 | 2013 | 934 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 1193 | 0.100 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2012 | 300 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2016 | 408 | 0.100 |
Why?
|
| Electroencephalography | 3 | 2009 | 6282 | 0.100 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 39312 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2017 | 1188 | 0.090 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 4421 | 0.090 |
Why?
|
| Bioethics | 1 | 2012 | 118 | 0.090 |
Why?
|
| Verbal Learning | 2 | 2011 | 459 | 0.090 |
Why?
|
| Leg | 1 | 2016 | 1087 | 0.090 |
Why?
|
| Drug Administration Schedule | 5 | 2004 | 4853 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2198 | 0.090 |
Why?
|
| Indenes | 1 | 2011 | 59 | 0.090 |
Why?
|
| Glucose | 6 | 2019 | 4340 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5513 | 0.090 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2010 | 1104 | 0.090 |
Why?
|
| Analysis of Variance | 8 | 2013 | 6214 | 0.090 |
Why?
|
| Time Factors | 8 | 2021 | 40149 | 0.090 |
Why?
|
| Africa, Western | 1 | 2010 | 160 | 0.090 |
Why?
|
| Consensus | 1 | 2020 | 3208 | 0.090 |
Why?
|
| Smoking | 7 | 2019 | 9077 | 0.090 |
Why?
|
| Anorexia | 1 | 2010 | 153 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 2334 | 0.080 |
Why?
|
| Dopamine Antagonists | 1 | 2010 | 279 | 0.080 |
Why?
|
| Glucose Tolerance Test | 5 | 2012 | 1180 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2001 | 2743 | 0.080 |
Why?
|
| Body Mass Index | 10 | 2019 | 13050 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2012 | 2519 | 0.080 |
Why?
|
| Confusion | 1 | 2011 | 278 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2010 | 193 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 502 | 0.080 |
Why?
|
| Attention | 5 | 2011 | 2413 | 0.080 |
Why?
|
| Philosophy | 1 | 2009 | 69 | 0.080 |
Why?
|
| Disease Management | 2 | 2016 | 2533 | 0.080 |
Why?
|
| Facility Regulation and Control | 1 | 2008 | 25 | 0.080 |
Why?
|
| Obesity | 7 | 2011 | 13090 | 0.080 |
Why?
|
| Mental Health | 1 | 2023 | 3269 | 0.080 |
Why?
|
| Granulocytes | 1 | 2010 | 551 | 0.080 |
Why?
|
| Pyridines | 1 | 2000 | 2888 | 0.080 |
Why?
|
| Eating | 2 | 2012 | 1539 | 0.070 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 454 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2010 | 2921 | 0.070 |
Why?
|
| Galantamine | 1 | 2008 | 33 | 0.070 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 5888 | 0.070 |
Why?
|
| Dopamine Agonists | 1 | 2010 | 346 | 0.070 |
Why?
|
| Health Policy | 1 | 2020 | 2697 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 213 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1186 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 970 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 2 | 2004 | 145 | 0.070 |
Why?
|
| C-Reactive Protein | 4 | 2021 | 3853 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2014 | 1757 | 0.070 |
Why?
|
| Dioxoles | 1 | 2007 | 96 | 0.070 |
Why?
|
| Psychopathology | 1 | 2010 | 434 | 0.070 |
Why?
|
| Personality Assessment | 1 | 2009 | 646 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2023 | 36570 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4249 | 0.070 |
Why?
|
| Amiodarone | 1 | 2008 | 216 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2012 | 1140 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2008 | 250 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 8045 | 0.070 |
Why?
|
| Memory | 3 | 2011 | 2192 | 0.070 |
Why?
|
| Professional-Family Relations | 1 | 2010 | 500 | 0.070 |
Why?
|
| Informed Consent | 1 | 2012 | 1010 | 0.070 |
Why?
|
| Air Pollution | 1 | 2020 | 2377 | 0.060 |
Why?
|
| Consciousness | 1 | 2011 | 602 | 0.060 |
Why?
|
| Dibenzothiazepines | 1 | 2006 | 102 | 0.060 |
Why?
|
| Sulfones | 1 | 2008 | 447 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2010 | 871 | 0.060 |
Why?
|
| Radiography | 2 | 2019 | 6968 | 0.060 |
Why?
|
| Ownership | 1 | 2008 | 338 | 0.060 |
Why?
|
| Social Environment | 1 | 2010 | 1012 | 0.060 |
Why?
|
| Self Concept | 1 | 2011 | 1040 | 0.060 |
Why?
|
| Atrophy | 2 | 2021 | 1631 | 0.060 |
Why?
|
| Severity of Illness Index | 5 | 2010 | 15912 | 0.060 |
Why?
|
| China | 2 | 2023 | 2386 | 0.060 |
Why?
|
| Capsules | 1 | 2005 | 192 | 0.060 |
Why?
|
| Anxiety | 2 | 2010 | 4668 | 0.060 |
Why?
|
| Sulpiride | 1 | 2004 | 13 | 0.060 |
Why?
|
| Dyskinesias | 1 | 2005 | 79 | 0.060 |
Why?
|
| Culture | 1 | 2009 | 622 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3235 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18397 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 949 | 0.060 |
Why?
|
| Adolescent | 8 | 2021 | 88902 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 956 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 849 | 0.060 |
Why?
|
| Risk Factors | 8 | 2021 | 74889 | 0.060 |
Why?
|
| Brain | 3 | 2009 | 27158 | 0.060 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2021 | 108 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1794 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2846 | 0.060 |
Why?
|
| Prevalence | 4 | 2009 | 15835 | 0.060 |
Why?
|
| Work Schedule Tolerance | 1 | 2008 | 553 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4810 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2007 | 1531 | 0.060 |
Why?
|
| Diphenhydramine | 1 | 2004 | 61 | 0.060 |
Why?
|
| Cycloserine | 1 | 2004 | 118 | 0.060 |
Why?
|
| Life Change Events | 2 | 2008 | 956 | 0.060 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2007 | 252 | 0.060 |
Why?
|
| Poisoning | 1 | 2005 | 254 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2011 | 2741 | 0.050 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 364 | 0.050 |
Why?
|
| Morbidity | 2 | 2009 | 1754 | 0.050 |
Why?
|
| Hyperlipidemias | 2 | 2005 | 771 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2010 | 1193 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 987 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2024 | 81657 | 0.050 |
Why?
|
| Gyrus Cinguli | 1 | 2009 | 1118 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 4056 | 0.050 |
Why?
|
| United States | 7 | 2017 | 72945 | 0.050 |
Why?
|
| Viral Load | 1 | 2012 | 3385 | 0.050 |
Why?
|
| Workload | 1 | 2008 | 849 | 0.050 |
Why?
|
| Antiemetics | 1 | 2004 | 187 | 0.050 |
Why?
|
| Wakefulness | 1 | 2009 | 1282 | 0.050 |
Why?
|
| Motor Activity | 1 | 2012 | 2711 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2010 | 2001 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 998 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 2204 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2003 | 4019 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2171 | 0.050 |
Why?
|
| Thiazoles | 1 | 2009 | 1529 | 0.050 |
Why?
|
| Adiposity | 1 | 2011 | 1892 | 0.050 |
Why?
|
| Neurochemistry | 1 | 2001 | 29 | 0.050 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 360 | 0.050 |
Why?
|
| Prognosis | 3 | 2009 | 29959 | 0.050 |
Why?
|
| Aerosols | 1 | 2004 | 634 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2004 | 1019 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 2030 | 0.050 |
Why?
|
| Folic Acid | 2 | 2006 | 1337 | 0.050 |
Why?
|
| Hyperhidrosis | 1 | 2001 | 34 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 3411 | 0.040 |
Why?
|
| Headache | 2 | 2015 | 1260 | 0.040 |
Why?
|
| Triglycerides | 3 | 2019 | 2441 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3468 | 0.040 |
Why?
|
| Mental Recall | 1 | 2006 | 1218 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 904 | 0.040 |
Why?
|
| Age of Onset | 1 | 2007 | 3343 | 0.040 |
Why?
|
| Body Composition | 3 | 2019 | 2441 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2013 | 2817 | 0.040 |
Why?
|
| Quality Improvement | 2 | 2012 | 3850 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 1883 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 21162 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 5873 | 0.040 |
Why?
|
| Inflammation | 3 | 2021 | 10863 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2021 | 444 | 0.040 |
Why?
|
| Weight Loss | 1 | 2010 | 2712 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 418 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 5502 | 0.040 |
Why?
|
| Motivation | 1 | 2009 | 2020 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9407 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 2224 | 0.040 |
Why?
|
| Psychomotor Performance | 4 | 2008 | 1885 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 59548 | 0.040 |
Why?
|
| Energy Intake | 1 | 2006 | 2142 | 0.040 |
Why?
|
| Students, Medical | 1 | 2011 | 1962 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2021 | 368 | 0.040 |
Why?
|
| Employment | 1 | 2004 | 1110 | 0.040 |
Why?
|
| Lung | 1 | 2016 | 10068 | 0.040 |
Why?
|
| Glycemic Index | 1 | 2020 | 400 | 0.040 |
Why?
|
| Troponin | 1 | 2021 | 536 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 2001 | 951 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 13489 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 542 | 0.040 |
Why?
|
| Emotions | 1 | 2009 | 2758 | 0.040 |
Why?
|
| Mental Health Services | 2 | 2013 | 1728 | 0.030 |
Why?
|
| Waist-Hip Ratio | 2 | 2010 | 521 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2004 | 1540 | 0.030 |
Why?
|
| Absorptiometry, Photon | 2 | 2013 | 1707 | 0.030 |
Why?
|
| Students | 1 | 2006 | 1741 | 0.030 |
Why?
|
| Sex Factors | 3 | 2013 | 10619 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 3213 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 12246 | 0.030 |
Why?
|
| Community Mental Health Centers | 2 | 2006 | 93 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2019 | 913 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2019 | 421 | 0.030 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 712 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 5098 | 0.030 |
Why?
|
| Drug Costs | 1 | 2003 | 1194 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2006 | 2903 | 0.030 |
Why?
|
| Risk | 2 | 2007 | 9602 | 0.030 |
Why?
|
| Cardiovascular Diseases | 3 | 2012 | 15652 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2228 | 0.030 |
Why?
|
| Health Status | 4 | 2009 | 4087 | 0.030 |
Why?
|
| Cholesterol | 3 | 2009 | 2904 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 551 | 0.030 |
Why?
|
| Sample Size | 2 | 2007 | 844 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2006 | 3208 | 0.030 |
Why?
|
| Hand | 1 | 2019 | 910 | 0.030 |
Why?
|
| Principle-Based Ethics | 1 | 2012 | 12 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 8540 | 0.030 |
Why?
|
| Paternalism | 1 | 2012 | 49 | 0.030 |
Why?
|
| Head | 1 | 2019 | 926 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2004 | 3079 | 0.030 |
Why?
|
| Nutrition Assessment | 2 | 2006 | 739 | 0.030 |
Why?
|
| Reference Standards | 1 | 1996 | 1010 | 0.020 |
Why?
|
| Laboratories | 1 | 1996 | 463 | 0.020 |
Why?
|
| Patient Rights | 1 | 2012 | 126 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2001 | 1648 | 0.020 |
Why?
|
| Fear | 1 | 2021 | 1496 | 0.020 |
Why?
|
| Medical Audit | 1 | 2013 | 454 | 0.020 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 2105 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2012 | 3681 | 0.020 |
Why?
|
| Logistic Models | 3 | 2012 | 13276 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2001 | 1209 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 1997 | 1050 | 0.020 |
Why?
|
| Fasting | 2 | 2007 | 1609 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 5536 | 0.020 |
Why?
|
| Incidence | 3 | 2007 | 21527 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 502 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3139 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 2010 | 198 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 484 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 642 | 0.020 |
Why?
|
| Carbon Monoxide | 2 | 2007 | 560 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2008 | 31 | 0.020 |
Why?
|
| Chewing Gum | 1 | 2008 | 40 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2010 | 385 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 16044 | 0.020 |
Why?
|
| Genotype | 3 | 2008 | 13036 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2008 | 47 | 0.020 |
Why?
|
| Diet Records | 1 | 2010 | 425 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2004 | 41706 | 0.020 |
Why?
|
| Health Services | 1 | 2013 | 755 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13644 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2008 | 153 | 0.020 |
Why?
|
| Pteroylpolyglutamic Acids | 1 | 2007 | 9 | 0.020 |
Why?
|
| Food Preferences | 1 | 2010 | 397 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2006 | 176 | 0.020 |
Why?
|
| Methionine | 1 | 2008 | 569 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 678 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2007 | 328 | 0.020 |
Why?
|
| Reference Values | 2 | 2006 | 4914 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20710 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 18076 | 0.020 |
Why?
|
| Purines | 1 | 2008 | 615 | 0.010 |
Why?
|
| Patient Care Management | 1 | 2008 | 302 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2021 | 54872 | 0.010 |
Why?
|
| Periodicity | 1 | 2006 | 347 | 0.010 |
Why?
|
| Cause of Death | 2 | 2005 | 3717 | 0.010 |
Why?
|
| Seizures | 1 | 1997 | 2996 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2004 | 90 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 1742 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3715 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2011 | 8533 | 0.010 |
Why?
|
| Hospitalization | 3 | 2016 | 10816 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 1175 | 0.010 |
Why?
|
| Caffeine | 1 | 2006 | 702 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 2783 | 0.010 |
Why?
|
| Hypertension | 2 | 2015 | 8616 | 0.010 |
Why?
|
| Patient Transfer | 1 | 2008 | 789 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2010 | 22248 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 627 | 0.010 |
Why?
|
| Lipids | 1 | 2011 | 3322 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2009 | 1389 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3624 | 0.010 |
Why?
|
| Prediabetic State | 1 | 2006 | 547 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2233 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2350 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 2392 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2005 | 886 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4114 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6329 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 10384 | 0.010 |
Why?
|
| Urban Population | 1 | 2006 | 2040 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5389 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24299 | 0.010 |
Why?
|
| Overweight | 1 | 2009 | 2447 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9661 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2006 | 1621 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2005 | 1188 | 0.010 |
Why?
|
| Nerve Net | 1 | 2009 | 2307 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 2645 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12064 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 3828 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4252 | 0.010 |
Why?
|
| Homeostasis | 1 | 2006 | 3343 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2008 | 4427 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15425 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10101 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16722 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3927 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 6597 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2005 | 5915 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 8928 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 14762 | 0.000 |
Why?
|
| Animals | 1 | 2021 | 168939 | 0.000 |
Why?
|
| Aging | 1 | 2006 | 8728 | 0.000 |
Why?
|
| Diet | 1 | 2004 | 8088 | 0.000 |
Why?
|